Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air

Authors: Andrea Princivalle, Lorenzo Monasta, Giovanni Butturini, Claudio Bassi, Luigi Perbellini

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

In the last decade many studies showed that the exhaled breath of subjects suffering from several pathological conditions has a peculiar volatile organic compound (VOC) profile. The objective of the present work was to analyse the VOCs in alveolar air to build a diagnostic tool able to identify the presence of pancreatic ductal adenocarcinoma in patients with histologically confirmed disease.

Methods

The concentration of 92 compounds was measured in the end-tidal breath of 65 cases and 102 controls. VOCs were measured with an ion-molecule reaction mass spectrometry. To distinguish between subjects with pancreatic adenocarcinomas and controls, an iterated Least Absolute Shrinkage and Selection Operator multivariate Logistic Regression model was elaborated.

Results

The final predictive model, based on 10 VOCs, significantly and independently associated with the outcome had a sensitivity and specificity of 100 and 84% respectively, and an area under the ROC curve of 0.99. For further validation, the model was run on 50 other subjects: 24 cases and 26 controls; 23 patients with histological diagnosis of pancreatic adenocarcinomas and 25 controls were correctly identified by the model.

Conclusions

Pancreatic cancer is able to alter the concentration of some molecules in the blood and hence of VOCs in the alveolar air in equilibrium. The detection and statistical rendering of alveolar VOC composition can be useful for the clinical diagnostic approach of pancreatic neoplasms with excellent sensitivity and specificity.
Appendix
Available only for authorised users
Literature
1.
Stewart RD. The use of breath analysis in clinical toxicology, in Wayland I, Hayes J (ed): Essay in toxicology. NY Academic Press; 1974. P. 121–147.
2.
Perbellini L, Faccini GB, Pasini F, Cazzoli F, Pistoia S, Rosellini R, Valsecchi M, Brugnone F. Environmental and occupational exposure to benzene by analysis of breath and blood. Brit J Ind Med. 1988;45:345–52.
3.
Droz PO, Guillemin MP. Occupational exposure monitoring using breath analysis. J Occup Med. 1986;28:593–602.CrossRefPubMed
4.
Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ. Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem. 1985;31:1278–82.PubMed
5.
Phillips M, Gleeson K, Hughes JMB, Greenberg J, Cataneo RN, Baker L, McVay WP. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999;353:1930–3.CrossRefPubMed
6.
Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN. Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Sci Appl. 1999;729:75–88.CrossRefPubMed
7.
Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C. Volatile markers of breast cancer in the breath. Breast J. 2003;9:184–91.CrossRefPubMed
8.
Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN. Detection of lung cancer with volatile markers in the breath. Chest. 2003;123:2115–23.CrossRefPubMed
9.
Netzer M, Millonig G, Osl M, Pfeifer B, Praun S, Villinger J, Vogel W, Baumgartner C. A new ensemble-based algorithm for identifying breath gas marker candidates in liver disease using ion molecule reaction mass spectrometry (IMR-MS). Bioinformatics. 2009;25:941–7.CrossRefPubMed
10.
Phillips M, Basa-Dalay M, Bothamley G, Cataneo RN, Lam PK, Natividad MPR, Schmitt P, Wai J. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis. 2010;90:145–51.CrossRefPubMed
11.
Phillips M, Erickson GA, Sabas M, Smith JP, Greenberg J. Volatile organic compounds in the breath of patients with schizophrenia. J Clin Pathol. 1995;48:466–9.CrossRefPubMedPubMedCentral
12.
Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass A, Greenberg J, Kobashigawa J, et al. Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardiol. 2004;94:1593–4.CrossRefPubMed
13.
14.
Paredi P, Kharitonov SA, Leak D, Shah PL, Cramer D, Hodson ME, Barnes JP. Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction. Am J Respir Crit Care Med. 2000;161:1247–51.CrossRefPubMed
15.
Moretti M, Phillips M, Abouzeid A, Cataneo RN, Greenberg J. Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia. Am J Obstet Gynecol. 2004;190:1184–90.CrossRefPubMed
16.
Mazzone PJ, Hammel J, Dweik R, Na J, Czich C, Laskowski D, Mekhail T. Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax. 2007;62:565–8.CrossRefPubMedPubMedCentral
17.
Taivans I, Jurka N, Balode L, Bukovskis M, Kopeika U, Ogorodniks V, Kleperis J, Strazda G, Šiliņš V, Martinsons A. Exhaled air analysis in patient with different lung diseases using artificial odour sensors. Proc Latuian Acad Sci Section B. 2009;63:210–3.
18.
Peng G, Hakim M, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Tisch U, Haick H. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Brit J Cancer. 2010;103:542–51.CrossRefPubMedPubMedCentral
19.
20.
Hornuss C, Praun S, Villinger J, Dornauer A, Moehnle P, Dolch M, Weninger E, Chouker A, Feil C, Briegel J, et al. Real-time monitoring of propofol in expired air in humans undergoing total intravenous anesthesia. Anesthesiology. 2007;106:665–74.CrossRefPubMed
21.
22.
Tibshirani R. Regression shrinkage and selection via the lasso. J R Statist Soc B Stat Methodol 1996;58:267–88.
23.
Goeman JJ. L1 penalized estimation in the cox proportional hazards model. Biom J. 2010;52:70–84.PubMed
24.
Huang J, Ma S, Zhang C. The Iterated Lasso for high-dimensional logistic Regression. 2008. Department of Statistics and Actuarial Science, The University of Iowa: Technical Report No. 392.
25.
Zou H. The adaptive lasso and its Oracle properties. Iowa City: J Am Stat Assoc. 2006;101:1418–29.
26.
27.
Brugnone F, Perbellini L, Apostoli P, Gaffuri E. Monitoring of industrial exposure to organic volatile compounds by analysis of alveolar air and blood. In: Ho MH, Dillon HK, editors. Biological monitoring of exposure to chemicals, Vol I: organic compounds. NY: John Wiley & Sons; 1987. p. 59–71.
28.
Brugnone F, Perbellini L, Faccini GB, Pasini F, Maranelli G, Romeo L, Gobbi M, Zedde. Breath and blood levels of benzene, toluene, cumene and styrene in non-occupational exposure. Int Arch Occup Environ Health. 1989;61:303–11.CrossRefPubMed
29.
30.
Kushch I, Arendacká B, Stolc S, Mochalski P, Filipiak W, Schwarz K, Schwentner L, Schmid A, Dzien A, Lechleitner M, et al. Breath isoprene - aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med. 2008;46:1011–8.CrossRefPubMed
31.
Ligor M, Ligor T, Bajtarevic A, Ager C, Pienz M, Klieber M, Denz H, Fiegl M, Hilbe W, Weiss W, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med. 2009;47:550–60.CrossRefPubMed
32.
Leaderer BP, Naeher L, Jankun T, Balenger K, Holford TR, Toth C, Sullivan J, Wolfson JM, Koutrakis P. Indoor, outdoor, and regional summer and winter concentration of PM10, PM2.5, SO4(2)-, H+, NH4+, NO3-, NH3, and nitrous acid in homes with and without kerosene space heaters. Environ Health Perspect. 1999;107:223–31.PubMedPubMedCentral
33.
Salem AA, Soliman AA, El-Haty IA. Determination of nitrogen dioxide, sulfur dioxide, ozone, and ammonia in ambient air using the passive sampling method associated with ion chromatographic and potentiometric analyses. Air Qual Atmos Health. 2009;2:133–45.CrossRefPubMedPubMedCentral
34.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed
35.
Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456–62.CrossRefPubMed
36.
Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, Endo M, Tsuchida A, Aoki T, Itoi T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005;65:10613–22.CrossRefPubMed
37.
Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol. 2007;23:508–21.CrossRefPubMed
38.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.CrossRefPubMed
39.
Kawai S, Suzuki K, Nishio K, Ishida Y, Okada R, Goto Y, Naito M, Wakai K, Ito Y, Hamajima N. Smoking and serum CA 19-9 levels according to Lewis and secretor genotypes. Int J Cancer. 2008;123:2880–4.CrossRefPubMed
40.
Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an symptomatic population. J Gastroenterol Hepatol. 2004;19:182–6.CrossRefPubMed
41.
Baker SG, Kramer BS, McIntosh M, Patterson BH, Shir Y, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials. 2006;3:43–56.CrossRefPubMed
42.
Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer. 2003;33:3–14.CrossRefPubMed
43.
Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–69.CrossRefPubMed
Metadata
Title
Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air
Authors
Andrea Princivalle
Lorenzo Monasta
Giovanni Butturini
Claudio Bassi
Luigi Perbellini
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4452-0

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study

Research article

Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma

Case report

Diffuse parenchymal pulmonary amyloidosis associated with multiple myeloma: a case report and systematic review of the literature

Research article

Feasibility, useability and acceptability of technology-based interventions for informal cancer carers: a systematic review

Research article

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Research article

Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits